ZPD A/S
CVR 32834825 · Public limited company (A/S) · Active · Low risk
ZPD A/S is a Public limited company (A/S), founded on , based in Esbjerg. The company is registered in the industry fremstilling af farmaceutiske råvarer. Our model estimates a bankruptcy risk of 0.0% over the next 12 months, which is 0.0 times the average for Danish companies. 16 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 217.6m and a net result of DKK 10.2m. CEO: Hiroyuki Shinya.
Bankruptcy risk for ZPD A/S
0.0 × the average (1.41%) · higher risk than 0% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 32834825
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (16 years)
- Address
- H E Bluhmes Vej 63
6700 Esbjerg - Municipality
- Esbjerg
- Industry
- Fremstilling af farmaceutiske råvarer (211000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 1.0m
- Employees
- 33 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 16 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 92.2% |
| Current ratio | 1,588% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 10 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 1 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK 52.7m | DKK 49.3m |
| Net profit | DKK 10.2m | DKK 12.9m |
| Equity | DKK 217.6m | DKK 208.9m |
| Total assets | DKK 236.1m | DKK 221.0m |
| Cash | DKK 102.9m | – |
| Short-term debt | DKK 12.0m | – |
| Avg. employees | 48 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 86 | ||
| 1 Jan 2024 – 31 Dec 2024 | 83 | ||
| 1 Jan 2023 – 31 Dec 2023 | 94 | ||
| 1 Jan 2022 – 31 Dec 2022 | 89 | ||
| 1 Jan 2021 – 31 Dec 2021 | 150 | ||
| 1 Jan 2020 – 31 Dec 2020 | 161 | ||
| 1 Jan 2019 – 31 Dec 2019 | 121 | ||
| 1 Jan 2018 – 31 Dec 2018 | 91 | ||
| 1 Jan 2017 – 31 Dec 2017 | 93 | ||
| 1 Jan 2016 – 31 Dec 2016 | 115 | ||
| 1 Jan 2015 – 31 Dec 2015 | 104 | ||
| 1 Jan 2014 – 31 Dec 2014 | 141 | ||
| 1 Jan 2013 – 31 Dec 2013 | 92 | ||
| 1 Jan 2012 – 31 Dec 2012 | 97 | ||
| 1 Jul 2010 – 31 Dec 2011 | 164 | ||
| 1 Jul 2009 – 30 Jun 2010 | 159 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Hiroyuki Shinya | Current | |
| CEO | Peter Rørvig | ||
| CEO | Robert Villum Nielsen | ||
| CEO | Helle Rørvig | ||
| CEO | Frank Marek | ||
| CEO | Ryu Nakao | ||
| Board | Frank Marek | Current | |
| Board | Masakazu Sakurai | Current | |
| Board | Ken Motegi | Current | |
| Board | Svend Blankholm | ||
| Board | Niels Ulrik Heine | ||
| Board | Peter Rørvig | ||
| Board | Helle Rørvig | ||
| Board | Mitsuhiro Tago | ||
| Board | Shigeya Furuhata | ||
| Board | Elio Ramon Loo | ||
| Board | Nobuhito Hashimoto | ||
| Board | Akihisa Ono | ||
| Board | Hiroyasu Nishioka | ||
| Board | Keiji Ishiyama | ||
| Board | Makoto Kishimoto | ||
| Board | Junkichi Izumi | ||
| Board | Katsuyuki Ishii | ||
| Board | Hiroki Kato | ||
| Board | Yoshihiro Hiraga | ||
| Board | Mitsuru Iwai | ||
| Board | Ken Motegi | ||
| Board | Kenichi Suzuki | ||
| Owner (100%) | Zeria Pharmaceutical Co. Ltd. | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB |
The CEOs' other companies
Peter Rørvig – 9 other companies
- A/S ORTHANA KEMISK FABRIK Active
- BIOFAC A/S Active
- BIOFAC HOLDING A/S Fusioneret
- DANIPHARM A/S Active
- H&P Rørvig Holding A/S Active
- N. THIESEN HOLDING A/S Active
- PHARMADAN A/S Active
- PHARMADAN ApS Fusioneret
- R & S PHARMADAN ApS Fusioneret
Helle Rørvig – 5 other companies
- A/S ORTHANA KEMISK FABRIK Active
- BIOFAC A/S Active
- DANIPHARM A/S Active
- H&P Rørvig Holding A/S Active
- PHARMADAN A/S Active
Frank Marek – 1 other companies
- JoinHealth ApS Active
Address history (3 moves)
| H E Bluhmes Vej 63, 6700 Esbjerg | |
| Englandsvej 350, 2770 Kastrup | |
| H E Bluhmes Vej 63, 6700 Esbjerg | |
| Englandsvej 350, 2770 Kastrup |
Former names
| ZPD A/S | – now |
| BIOFAC ESBJERG A/S | – |
Employees per year
Other companies at the same address
- JoinHealth ApS Active
Similar companies in Esbjerg
- Glycom Manufacturing A/S Esbjerg N
Questions and answers about ZPD A/S
Has ZPD A/S gone bankrupt?
No, ZPD A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of ZPD A/S?
Our model estimates a bankruptcy risk of 0.0% over the next 12 months (low risk), which is 0.0 times the average for Danish companies.
Who is the CEO of ZPD A/S?
Hiroyuki Shinya is the CEO of ZPD A/S.
Who is the auditor of ZPD A/S?
ZPD A/S most recently used EY Godkendt Revisionspartnerselskab.
When was ZPD A/S founded?
ZPD A/S was founded on 4 March 2010.
What is the equity of ZPD A/S?
Equity was DKK 217.6m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.